Traders should monitor progress of the EscharEx Phase III trial and regulatory approvals for the new NexoBrid facility as key near-term catalysts. While cash is strong, continued revenue declines and negative EBITDA suggest ongoing execution risk. The reaffirmed guidance provides some forward hope, but near-term fundamentals are weak.
Price Chart
Executive Summary
MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. government shutdown and reduced product sales to Vericel. Despite higher R&D spending on the EscharEx Phase III trial, the company maintained a strong cash position of $53.6 million and reaffirmed its 2026–2028 revenue guidance. The stock remains speculative, tied to upcoming clinical and regulatory catalysts.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $1.9 million, down 67% from $5.8 million in Q4 2024
- Full-year 2025 revenue was $17.0 million, down from $20.2 million in 2024
- Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024
- Cash balance increased to $53.6 million at year-end, up from $43.6 million, due to a $30 million registered direct offering
- Company reaffirmed 2026 revenue guidance of $24–26 million, $32–35 million in 2027, and $50–55 million in 2028
- EscharEx Phase III VALUE trial progressing with enrollment and interim assessment expected by end of 2026
- Expanded NexoBrid manufacturing facility now operational, with sixfold capacity increase; regulatory approvals expected in 2026
Financial Impact
Revenue declined 15.8% YoY to $17.0 million; operating loss widened to $25.3 million from $19.4 million in 2024
Risk Factors
- Revenue heavily impacted by U.S. government budget delays; future development revenue remains uncertain
- EscharEx approval and commercial success are not guaranteed; clinical or regulatory setbacks could significantly impact valuation
- High R&D spend ($14.3M in 2025) continues to drive losses despite lower SG&A
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250013 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 17w ago | Insider Cluster | $13.76 $12.70 | ▼ −7.70% | ▼ −8.82% | $13.52 (−1.74%) |
May 27, 2026 18w ago | Press Release | $14.33 $13.12 | ▲ +8.48% | ▲ +10.36% | $13.52 (+5.65%) |
May 7, 2026 21w ago | Press Release | $17.27 $14.22 | ▼ −17.66% | ▼ −21.49% | $13.52 (−21.71%) |
Mar 30, 2026 26w ago | 6-K | $16.11 $15.19 | ▼ −5.71% | ▼ −18.09% | $13.52 (−16.08%) |
Mar 5, 2026 30w ago | Press Release | $17.03 $13.82 | ▼ −18.85% | ▼ −31.63% | $13.52 (−20.61%) |
Mar 5, 2026 30w ago | Press Release | $17.45 $13.82 | ▲ +20.80% | ▲ +32.10% | $13.52 (+22.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access